Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Several possible studies

Story checked

First generic combo hormone patch could make menopause relief more affordable (opens in a new tab)

medicalxpress.com · 2026-10-21

Short answerEvidenceSource

Short answer

Several possible studies

Study not confirmed.

Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.

19 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Multiple potential source studies identified.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

View article claims
3

Search result

Several studies could fit.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

The literature search

19 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 15 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 5Not checkedThe FDA approved the first generic version of Climara Pro, a weekly hormone patch, which could make menopause relief more affordable.View evidenceHide evidence

As statedfirst generic version; more affordable

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 5Not checkedThe generic patch delivers estradiol and levonorgestrel and works the same way as the brand-name version.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 5Not checkedIt is approved for women who still have a uterus to treat moderate to severe hot flashes and night sweats caused by menopause, and to help prevent osteoporosis.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 5Not checkedThe article says adding a progestin to estrogen helps protect the uterine lining and against uterine cancer in women with a uterus.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 5Not checkedThe FDA is also working to change how hormone therapy risks are presented, including removing language about heart disease, breast cancer and probable dementia from boxed warnings, while still listing those risks elsewhere on the label.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Clinical Evaluation of Low-Dose 17-Beta Estradiol Matrix Transdermal Therapeutic System in the Management of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women

Menopause · 1999 · Crossref

Source (opens in a new tab)
Candidate

Safety and efficacy of a continuous once-a-week 17??-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials

Menopause · 2002 · Crossref

Tessa (opens in a new tab)Source (opens in a new tab)

Explore all search results